[22] compared glucose metabolism parameters and post-prandial GLP-1 levels before and after MBS between patients with active or inactive Crohns Disease and healthy controls
But GIP receptors are also expressed on adipocytes, which gives these drugs additional metabolic effects. UAB at the forefront of GLP-1 research In December 2025, the FDA approved an oral version of GLP-1 semaglutide
The trial demonstrated dose-dependent weight loss, with participants receiving 12 mg achieving a mean body weight reduction of approximately 24% over 48 weeks a result that has attracted considerable scientific and public interest
IBD is associated with the dysregulation of the symbiotic relationship between the commensal ecosystem and the mucosal immune system ( Crohns disease (CD) and ulcerative colitis (UC) are the two major phenotypes of IBD, and they differ meaningfully in their biology, barrier injury patterns, and epithelial restitution mechanisms
It can take months to show up
This makes it especially relevant in research focused on incretin biology, glucose homeostasis, energy expenditure and next-generation obesity models
